Drug Trial Radar · NCT07061574
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 10, 2026
Primary completion
Apr 15, 2030
Study completion Apr 15, 2031
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jaeb Center for Health Research
- First posted
- Jul 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.
Conditions
- Type 1 Diabetes
- New Onset
Interventions
Anti-thymocyte globulin (ATG)Drug
ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. The first dose (0.5 mg/kg) will be infused on day 0, during a period of 6 hours. The second dose (2 mg/kg) will be given on day 1, over a period of 4 to 6 hours.
verapamil extended-release capsuleDrug
Daily oral (pill) administration at 60, 120, 240 or 360 mg based on weight and ECG findings.
AdalimumabDrug
40 mg administered subcutaneously every other week beginning 6 weeks after the last dose of ATG until the 156-week visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stimulated C-peptide AUCTime frame: Week 104
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
UCLA
Los Angeles, California · Not yet recruiting
UCSF
San Francisco, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Florida
Gainesville, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
Indiana University
Indianapolis, Indiana · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
University of Buffalo
Buffalo, New York · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Texas Children's Hospital/Baylor College of Medicine
Houston, Texas · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.